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40 mg/m2, d1;d8, or paclitaxel 175mg/m2, d1) plus cisplatin (CDDP, 
25mg/m2, d2-4). Patients were divided into chemoresponsive (CR+PR) 
and chemoresistant (SD+PD) groups according to objective response 
status which was evaluated by RECIST system. Tumor cells from 
specimens of bronchoscopic, surgical biopsy and pleural effusion cell 
collection had been cultured and treated with DC in vitro. The m-P53of 
culture supernatant was measured by ABC-ELISA kit before DC treat-
ment. The telomerase activity was determined by the telomeric repeat 
ampliﬁcation protocol (TRAP) based PCR-ELISA kit and apoptosis 
was determined by TdT-mediated d-UTP-X nick-end labeling (TU-
NEL) Assay. Data represent as both actual detected and positive value. 
The senescence of tumor cells deﬁned as that, apoptosis rate increased 
more than 50% to control, and telomerase activity decreased less than 
50% to control. 
Results: There was no signiﬁcant deference between clinical treatment 
response and sex, pathological type, specimen origin, or m-P53 status 
in cultured cell supernatant. Telomerase activity and apoptosis rate was 
positive in 61.1% (41/67) and 25.4% (17/67) of all samples respec-
tively. A signiﬁcant difference of senescence of tumor cells treated by 
DC, was existed between chemoresponsive and chemoresistant patients 
groups (P<0.05). Multinomial logistic regression analyses shown that 
telomerase activity decreased less than 50% in vitro may be an indica-
tor of clinical response for taxanes plus cisplatin chemotherapy. Odds 
ratio is 4.226, p<0.05. 
Conclusion: For NSCLC, chemotherapy induced lung cancer tu-
mor cells senesce in vitro may be a promising predicator for clinical 
response. The relationship between clinical response and detectable 
m-P53 in vitro still is obscure.
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Background: Gemcitabine and paclitaxel were both active for ad-
vanced nonsmall cell lung cancer (NSCLC) patients. Combinations 
of gemcitabine and paclitaxel with various doses and schedules were 
shown to be effective treatment for these patients. The survival out-
come of these patients are not clear.
Methods: Patients with advanced NSCLC in a phase II study of 
weekly paclitaxel and gemcitabine as ﬁrst-line treatment were followed 
until their death. Second or further lines of treatment were recorded. 
Results: Thirty-seven patients were accrued receiving a total of 188 
cycles of gemcitabine and paclitaxel treatment. Toxicities were mild. 
Twenty-three patients had partial response (overall response rate, 62%; 
95% conﬁdence interval, 46-78%). Median time to treatment failure 
was 6.0 months. Twenty-seven (73%) patients received second-line 
anticancer drug treatment. Twenty-three (62%) patients were able to 
receive platinum doublet. Median survival after second-line treat-
ment was 10.9 months. Median, 1- and 2-year survival of 37 patients 
were16.8 months, 59% and 27%. There was a statistically signiﬁcant 
difference in median survival between patients who can or cannot 
receive second-line treatment (21.9 vs. 3.1 months, p < 0.00001). 
Conclusions: Weekly paclitaxel with gemcitabine is effective and well 
tolerated as ﬁrst-line treatment for advanced NSCLC patients. Long 
survival may be due to platinum doublet second-line chemotherapy.
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Background: Gemcitabine is active as second line therapy in NSCLC. 
Oxaliplatin may be non-cross resistant with other platinum agents used 
as ﬁrst-line therapy in NSCLC. The combination of gemcitabine and 
oxaliplatin (GEMOX) is synergistic in pre-clinical models and clinical 
trials have shown that it is safe and efﬁcacious in several tumor types, 
including NSCLC.
Methods: A phase II trial was designed to assess the efﬁcacy and 
tolerability of gemcitabine 1,000 mg/m2 over 100 min in combination 
with oxaliplatin 100 mg/m2 over 2 hours both given on days 1 and 
15 of a 28-day cycle. Patients with NSCLC were eligible if they had 
progressed after ﬁrst line treatment. Primary endpoint was objective 
response rate assessed by RECIST. Planned sample size is 30 patients 
over a period of 2 ½ years. Functional Assessment of Cancer Therapy-
Lung (FACT-L) v.4 questionnaire was used to assess the quality of life 
of patients on therapy.
Results: Twenty-two patients have been enrolled. 13 were men (59%) 
and 9 were women (41%). Fifteen patients were Hispanic (68%), four 
were Caucasian (18%), and 3 were African-American (13%). Median 
age was 55 years. Histologic subtypes were as follows: adenocarcino-
ma, 12; NSCLC not otherwise speciﬁed, 7; squamous cell carcinoma, 
3. Nine patients had an ECOG performance status (PS) of 0 (41%) and 
13 had a PS of 1 (59%). Two patients were never smokers. A total of 
56 cycles have been administered (median 2, range 1 to 6). GEMOX 
was given as second-line therapy to 18 patients (81%), and as third-line 
to 4 patients (18%). Twenty patients are available for assessment of 
response. Two patients had a conﬁrmed partial response (10%) and an-
other eight had stable disease (40%). Two patients died on study from 
disease progression leading to respiratory and multi-organ failure. The 
following Grade 3 and 4 adverse events were seen in 2 patients each: 
fatigue, dyspnea, anemia, and multi-organ failure. Preliminary results 
of FACT-L analysis in 19 pts show improvement in Lung Cancer Sub-
scale (LCS) score in 25% of the patients after 2 cycles of therapy.
Conclusions: Gemcitabine in combination with oxaliplatin is active 
and well tolerated as second and third line treatment for advanced 
NSCLC. Improvement of LCS score after 2 cycles suggests a clinical 
beneﬁt that is beyond the observed response rate of 10%.
